Marrow transplantation
involves the collection and reinfusion of multipotential hematopoietic stem cells (HSC) with the intent of replacing diseased bone marrow, marrow contaminated by tumor cells or marrow seriously impaired by cytotoxic chemotherapy or radiation (Thomas et al. 1975 ; Thomas 1983) . HSC have the capacity for continuous self renewal and in an appropriate microenvironment can give rise to progenitor cells capable of fully reconstituting the blood and immune systems. HSC are present in fetal liver and migrate to the bone marrow at the end of fetal life. Hematopoietic progenitor cells are usually not found in peripheral blood after birth, but they may be induced to circulate following chemotherapy or stimulation with hematopoietic growth factors such as granulocyte-colony stimulating factor (G-C SF ), granulocyte-macrophage-colony stimulating factor (GM-C SF) or interleukin 3 (IL-3) (Gianni et al. 1989 ). Lacking precise markers and functional assays it has not been possible to quantitate HSC in bone marrow or peripheral blood. It is not clear at this time if peripheral blood progenitor cells (PBPC) have the same capacity for continuous self renewal as HSC and whether PBPC are adequate for reconstituting sustained hematopoietic function in adults following marrow ablative therapy. If a patient has normal marrow function, his own HSC can be collected, cryopreserved and reinfused to rescue hematopoietis following high dose chemotherapy or total body irradiation. Reconstitution of hematopoietic function in this manner is referred to as an autologous marrow transplant (ABMT) ( Table 1) . If an ABMT is not feasible and the patient has an identical twin, a syngeneic transplant might be appropriate. In this situation the donor and recipient are genetically identi- 
Autologous marrow transplants
The major advantage of ABMT is the additional therapeutic margin it provides by allowing the use of unusually high dose (HD) chemotherapy and radiation. Following completion of HD therapy, cryopreserved autologous marrow cells are reinfused in the patient to replace damaged HSC and thereby rescue the patient from the otherwise fatal complications of severe marrow suppression or ablation. This approach to cancer therapy may be advantageous when active agents and drugs are available which demonstrate log linear antitumor dose responses, for example BCNTJ, busulfan, cyclophosphamide, etoposide, platinum, thiotepa and total body irradiation (TBI). These agents are ideal for ABMT assuming that HD therapy followed by HSC rescue can be accomplished without causing unacceptable non-hematological toxicity. The development of recombinant hematopoietic growth factors such as G-CSF, GM-CSF and IL-3 has also contributed significantly to the support of patients undergoing HD regimens. Randomized studies have proven that hematopoietic growth factors administered following ABMT can shorten the period of neutropenia and diminish other manifestations of HD drug and radiation toxicity (Nemunaitis et al. 1991) . ABMT has been proven to be effective treatment for patients with acute leukemia (AML and ALL), Hodgkin's disease, non-Hodgkin's lymphoma and neuroblastoma, and ABMT has shown promise as potentially curative therapy for patients with breast cancer, ovarian cancer and primary brain tumors. Studies are also underwent exploring the activity of ABMT in multiple myeloma and chronic myeloid leukemia (CML) ( Table 2 ). The presence of tumor cells in bone marrow is a potentially limiting factor in ABMT, because tumor cells reinfused with autologous marrow may be clonogenic and capable of causing recurrence of malignant disease in patients who may otherwise have been rendered tumor free by HD therapy. Methods for removing tumor cells have been based primarily on negative selection or purging. These include incubation of freshly collected marrow cells with specific monoclonal antibodies and complement, monoclonal antibodies complexed to magnetic beads, monoclonal antibodies conjugated to toxins such as ricin, diphteria or pseudomonas toxin, or treatment of marrow cells ex vivo with chemotherapeutic agents such as hydroxycyclophosphamide.
The in vitro manipulation of HSC and the treatment of HSC with cytotoxic agents may potentially damage HSC. Unfortunately, there are no in vitro methods available for assaying HSC activity and information on the efficacy of marrow purging is sparse. The quality of hematopoietic recovery after transplantation of purged autologous marrow has sometimes been marginal especially in patients with a prior history of high dose cytotoxic therapy and in patients with acute myeloid leukemia (AML).
Recently new approaches to facilitating engraftment after ABMT have been developed that involve the infusion of cryopreserved PBPC which have been collected following stimulation with hematopoietic growth factors such as G-CSF or GM-CSF. PBPC are collected by pheresis, cryopreserved and then reinfused along with cryopreserved autologous marrow cells following a course of HD chemotherapy with or without irradiation.
Additional growth factor is given for the first 14 to 21 days posttransplant.
The combination of autologous PBPC and hematopoietic growth factors significantly reduces the period of post-ABMT neutropenia and thrombocytopenia, and some of the regimen related toxicities seen in these patients may also be ameliorated. Studies are currently underway Allogeneic marrow transplants A marrow transplant from a normal donor other than an identical twin is referred to as an allogeneic transplant. Genetic differences which invariably occur between different individuals can induce immunological responses in both host and donor cells (Thomas et al. 1975) (Table 3) . Residual immune cells in the recipient may recognize donor specific alloantigens and the host-versus-graft reaction (HVG) which may result in graft failure or rejection. In addition, immunocompetent donor T cells present in the grafted marrow may recognize patient specific alloantigens and the immunological reaction that follows may cause graft-versus-host disease (GVHD). GVHD can contribute significantly to transplant-associated morbidity and mortality. To optimize the benefits of transplants from normal donors while minimizing immunological complications, most marrow allografts are performed only when an HLA identical sibling donor is available. The HLA system or human major histocompatibility complex controls the most important reactions to transplanted tissues (Martin et al. 1987 ). Unfortunately, the chance a sibling will be HLA identical is only 25%. It is possible to find HLA matches among unrelated donors, however very large numbers of HLA typed volunteers must be available as potential donors to provide a reasonable chance of finding matches for most patients (Beatty et al. 1988 ).
Marrow transplants from healthy donors have potential advantages over ABMT. First, tumor contamination of the marrow, or genetic abnormalities affecting hematopoietic or immune function can be avoided if the marrow donor is normal. Furthermore, the chance of posttransplant relapse may be less following transplantation from a normal allogeneic donor. Patients with certain kinds of leukemia or lymphoma are more likely to remain in remission if they develop GVHD (Weiden et al. 1979 ). This suppression of relapse is referred to as the TABLE 3 . Allogeneic marrow transplants graft-versus-leukemia effect (GVL). The mechanism of GVL is unknown, but presumably GVL like GVHD represents a consequence of the alloimmune response of donor T cells to certain genetic differences in the recipient. It is possible that tumor associated antigens are' targets fer GVL. Whether GVL and GVHD are caused by the same effector cells or represent distinct reactions that potentially can be disassociated and controlled in a way that would enhance the therapeutic effect and minimize the complications associated with GVHD is a critical question.
Established indications for transplants from HLA identical donors include inherited, acquired and malignant diseases (Table 4 ). Conditions such as severe combined immunodeficiency disease (SLID), thalassemia or aplastic anemia are diseases in which the patient has inadequate numbers of normal HSC. Definitive treatment of these patients has not been possible in the absence of a suitably matched normal donor.
Clinical results of marrow transplantation
The transplant conditioning regimen for patients with aplastic anemia treated in Seattle has been cyclophosphamide 50 mg/kg administered on each of four consecutive days followed by infusion of unmodified donor marrow cells 36 hr after the last dose of cyclophosphamide ). The current preferred method for GVHD prophylaxis is immunosuppression with methotrexate administered on days 1, 3, 6 and 11 and cyclosporine given daily for six months (Storb et al. 1986a ). Before 1975, graft rejection was a major cause of treatment failure. Risk of rejection was associated with previous blood transfusions and a (Storb et al. 1984 ). The rate of rejection was lower and survival was better in patients who had not been transfused (Table 5 ). More recently, antithymocyte globulin has been added to the conditioning regimen along with cyclophosphamide to reduce the chance of graft rejection. This has been successful and we are no longer using the infusion of additional bully coat cells.
The conditioning regimen for patients with leukemia treated in Seattle has been cyclophosphamide, 60 mg/kg on each of two consecutive days followed by 1200-1575 cGy TBI administered in fractions over periods of 3-7 days . One of the most successful methods for preventing GVHD in leukemic patients has been immunosuppression with the combination of methotrexate and cyclosporine (Storb et al. 1986b ). Table 5 shows the probability of survival for patients with various diseases treated with HLA-identical sibling marrow grafts. Approximately 10-15% of the patients with advanced chemotherapy resistant acute leukemia can be cured by an allogeneic marrow transplant, however, treatment failure eventually occurs in most of these patients because of leukemic relapse. Improved disease-free survival rates can be achieved if patients are treated earlier in the course of their disease. For example, 40-70% of the patients with acute myeloid leukemia (AML) transplanted in first marrow remission become disease-free survivors (Clift et al. 1990 ), and 30-60% of patients with acute lymphoblastic leukemia (ALL) transplanted in first or second remission become long-term disease-free survivors Doney et al. 1991 ). The optimal timing of a marrow transplant, however, should carefully consider patient characteristics and the outcome of alternate therapy. For example, 20-30% of AML patients who achieve a first marrow remission may be cured by chemotherapy only, and some patients failing chemotherapy may still be successfully rescued by marrow transplantation (Clift et al. in press ). The potential improvement in survival provided by a greater anti-leukemic effect of more intense conditioning regimens is limited by toxicity to normal organs and the increase in treatment-related deaths. Improvements in supportive therapy may benefit patients undergoing marrow transplantation or conventional chemotherapy thereby allowing more intensive and effective anti-tumor regimens. With parallel overall improvements and in both conventional chemotherapy and important marrow transplantation, the best timing for transplantation will continue to be an important and unsolved question. Patients at high risk for chemotherapy failure, such as patients with a high blast cell count at diagnosis, with M4-M7 subtypes of the French-American-British classification system or certain cytogenetic abnormalities such as a bcr-abl translocation in ALL are currently candidates for transplantation in first remission. It is likely, however, that the results of marrow transplantation may be diminished in patients with these poor prognosis risk factors.
For patients with CML, allogeneic marrow transplantation is the only known treatment modality capable of achieving disease-free survival at 5-10 years (Thomas and Clift 1989). The median life expectancy of patients treated with chemotherapy, splenectomy or spleen irradiation is 3-5 years. Treatment with alfa-interferon (IF a) results in complete remission in only 10-20% of the patients and it is not known how long IF a-responsive patients will benefit from this treatment. Patients transplanted for CML in chronic phase have a 60-90% probability of disease-free survival. The best results are achieved in younger patients transplanted within the first year of diagnosis. Complete success is still limited by leukemic relapse occurring in 10-30% of patients and by treatmentassociated toxic deaths in 15-30% of patients . Marrow transplants are less successful in patients with CML in blast phase with only 10% of the latter achieving disease-free survival at 5-10 years.
Transplants from HLA partially matched family members
The effect of HLA mismatches has been analyzed in patients with hematological disease transplanted from family members sharing with the patient one HLA haplotype (haploidentical) and differing for a variable number and type of HLA-A, B or DR antigens on the unshared haplotype ). The degree of VILA incompatibility has a direct correlation with the risks of graft rejection and GVHD, and an inverse correlation with survival. Patients with ALL who develop acute or chronic GVHD after transplantation from a haploidentical donor have a lower risk of leukemic relapse than patients without GVHD. Chronic but not acute GVHD has been associated with a lower relapse rate in patients with AML or CML. There is a trend for a lower relapse rate in haploidentical transplants compared to HLA identical sibling transplants. This may occur primarily because the incidence of GVHD is higher in haploidentical transplants.
In patients without GVHD the probability of leukemic relapse is similar, whether the marrow donor is an HLA-identical sibling or haploidentical relative. Thus, it appears that in absence of clinically significant acute GVHD HLA disparity per se confers no antileukemic effect.
Patients receiving one HLA locus incompatible transplants have a probability of survival identical to patients receiving transplants from HLA-identical siblings (Beatty et al. 1985) . Increased mortality from graft rejection and infection associated with GVHD is offset by a lower rate of leukemic relapse. In contrast, patients receiving transplants incompatible for two or three HLA loci have a lower probability of survival. More effective approaches to GVHD prevention will be needed so that safety and outcome of highly mismatched transplants can be improved.
Depletion of mature T cells from the donor marrow is effective in decreasing both acute and chronic GVHD and associated morbidity (Ash et al. 1991 ). However, except for patients with severe combined immunodeficiency, no significant improvement in disease-free survival has been achieved by a variety of T cell depletion protocols, because of an increased rate of marrow graft rejection and relapse of leukemia after transplantation (Martin and Kernan 1988) .
Transplants from HLA matched unrelated donors Less than 30% of the patients in North America have an HLA-matched sibling and 3-5% have a one HLA-locus mismatched relative. Therefore, for most patients in need of a normal donor transplant the only option is the identification of an HLA compatible unrelated volunteer. Increasing knowledge of the structure of HLA and development of new molecular typing technologies have allowed accurate matching of patients and unrelated donors. Initial case reports between 1973 and 1986 demonstrated that unrelated donor transplants could be done safely and effectively for patients with leukemia or other disorders of the lympho-hemopoietic system (Hansen et al. 1980) . Through the efforts of a large number of individuals and the support of federal funds, the U.S. National Marrow Donor Program has established a network of donor centers, transplant centers and a centralized file of HLA-typed volunteer donors (McCullough et al. 1989 ). As of June 1992, NMDP had accrued more than 600,000 volunteers typed for HLA-A and B, and faciliated more than 1200 unrelated donor transplants. More than 100,000 donors in the NMDP registry have also been typed for HLA-DR. The probability of finding an HLA-A, B, DR match at the initial search has increased from 10-15% in 1987, to 40-45% in 1992.
NMDP has reported the outcome of unrelated donor transplantation in patients with leukemia (Kernan et al. 1992 ). The probability of disease-free survival at 1.5 years was 45% in 58 patients with acute leukemia in first or second remission, and 19% in 98 patients with more advanced leukemia. CML has become the most common indication for an unrelated donor transplant. Although GVHD is increased in unrelated donor transplants, long-term diseasefree survival can be achieved by this treatment using either post-transplant immunosuppression alone or T cell depletion of the donor marrow and immunosuppression for GVHD prophylaxis (Ash et al. 1990; Beatty et al. 1991) . In Seattle, patients are conditioned with cyclophosphamide and TBI, transplanted with unmodified marrow, and cyclosporine plus methotrexate are used for GVHD prophylaxis (Beatty et al. , 1992 . Graft failure has occurred in 3% of unrelated donor transplants that are matched for HLA-A, B and DRB1 and 5% of HLA mismatched transplants. The probability of grades II-IV acute GVHD has been 75% for matched and 94% for mismatched transplants.
The KaplanMeier estimate of survival for patients transplanted with CML in chronic phase is 45 + 5% at 2-3 years, and no patient in this group has had clinical relapse. Disease-free survival has been less for CML patients transplanted in the accelerated or blast phase of disease.
Marrow transplants from HLA matched unrelated donors have a greater incidence of graft failure and GVHD than transplants from HLA identical siblings. These may be due to disparities for undetected HLA differences or to non-HLA linked minor histocompatibility genes. Because of the extraordinary polymorphism of the HLA system, HLA matched unrelated donors will not be found for all patients and some degree of donor and recipient HLA disparity will be inevitable in certain cases. Future research in this field must be aimed at developing improved methods for immunosuppression and GVHD prevention which will result in lower morbidity and better survival despite minimal degrees of HLA disparity.
